#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15502	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2518	750.2	0	.	n	.	0	A69G	SNP	69	69	A	578	578	G	1011	G,A	739,271	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15502	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2518	750.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1959	1959	T	989	T,C,G,A	983,3,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15502	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2518	750.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1693	1693	C	980	C,T	977,3	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	842.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1827	1827	A	1138	A,G	1137,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	842.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2461	2461	C	1016	C,T,A	1011,2,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	842.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2535	2535	A	931	A	931	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26722	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	842.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3087	3087	C	976	C,T,A	974,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2222	folP	852	852	99.88	folP.l15.c17.ctg.1	1932	143.2	0	.	p	.	0	E151K	NONSYN	451	453	GAA	969	971	AAA	224;224;222	A;A;A	224;224;222	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	2222	folP	852	852	99.88	folP.l15.c17.ctg.1	1932	143.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1200	1202	AGC	246;248;248	A;G,A,T;C	245;246,1,1;248	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4000	187.7	1	SNP	p	S91F	0	.	.	271	273	TCC	911	913	TCC	207;206;209	T;C;C	207;206;209	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4000	187.7	1	SNP	p	D95N	0	.	.	283	285	GAC	923	925	GAC	221;221;220	G;A;C	221;221;220	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6030	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	4000	187.7	1	SNP	p	D95G	0	.	.	283	285	GAC	923	925	GAC	221;221;220	G;A;C	221;221;220	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	2026	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1746	144.8	1	SNP	p	G45D	0	.	.	133	135	GGC	697	699	GGC	233;229;229	G;G;C	233;229;229	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1110	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1406	98.3	0	.	n	.	0	A197.	DEL	197	197	A	764	764	A	216	A	215	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5268	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3439	190.8	1	SNP	p	D86N	0	.	.	256	258	GAC	805	807	GAC	241;241;238	G;A;C,G	241;241;236,2	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5268	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3439	190.8	1	SNP	p	S87R	0	.	.	259	261	AGT	808	810	AGT	236;237;238	A;G;T,G	236;237;237,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5268	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3439	190.8	1	SNP	p	S87W	0	.	.	259	261	AGT	808	810	AGT	236;237;238	A;G;T,G	236;237;237,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5268	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3439	190.8	1	SNP	p	S87I	0	.	.	259	261	AGT	808	810	AGT	236;237;238	A;G;T,G	236;237;237,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5268	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3439	190.8	1	SNP	p	S88P	0	.	.	262	264	TCC	811	813	TCC	237;238;239	T,G;C,G;C	236,1;237,1;239	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4590	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3203	178.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1752	1754	GGC	275;269;268	G;G;C	274;268;267	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1329	1331	GCA	237;236;237	G,A;C,T;A,C	236,1;235,1;236,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1332	1334	ATC	237;235;237	A,C;T;C	236,1;235;237	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1344	1346	GTG	226;227;229	G;T,C,A;G,C	225;225,1,1;228,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1344	1346	GTG	226;227;229	G;T,C,A;G,C	225;225,1,1;228,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1848	1850	ACC	234;235;236	A,G;C;C,T	233,1;235;235,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1902	1904	GCG	224;224;224	G,A;C,T;G	223,1;223,1;224	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1902	1904	GCG	224;224;224	G,A;C,T;G	223,1;223,1;224	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2025	2027	GGC	235;236;239	G,T;G;C	234,1;236;239	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2034	2036	GGC	243;240;240	G;G,T;C	242;239,1;240	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4308	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2743	194.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2052	2054	CTG	230;228;227	C;T;G,A	230;228;226,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5930	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3634	203.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1926	1928	CCG	256;258;254	C;C,G;G	256;257,1;254	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2546	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2200	144.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	768	768	C	173	C,G	172,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	100	95.0	porB1a.l15.c4.ctg.3	180	51.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	131	133	ACG	66;65;62	A;C;G	66;65;62	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	100	95.0	porB1a.l15.c4.ctg.3	180	51.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	173	175	CAA	31;26;23	C;A;A	31;26;23	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	39;43;45	T;T;A	39;43;45	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	76;76;76	C;A;T	76;76;76	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	76;76;76	A;G;T	76;76;76	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	76;76;76	T;A;C	76;76;76	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	318	porB1a	984	226	90.27	porB1a.l15.c4.ctg.4	360	39.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	536	538	GAA	250;250;245	G;A,C;A	250;249,1;245	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	824	826	GAT	257;256;257	G,T;A;T,G	256,1;255;255,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	947	949	TCA	271;274;274	T;C,T;A	271;272,2;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	K207E	NONSYN	619	621	AAA	1043	1045	GAA	273;273;270	G;A,T;A,C,G	273;272,1;268,1,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	A218I	NONSYN	652	654	GCC	1076	1078	ATC	254;254;251	A,C;T,A;C,G	251,1;251,1;248,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1088	1090	TCT	247;246;248	T;C;T,A	247;246;247,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1406	1408	GCA	226;222;221	G;C,G;A,C	226;221,1;220,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	1	SNP	p	G120K	1	.	.	358	360	AAG	782	784	AAG	252;253;254	A,G;A;G,T,A	251,1;253;252,1,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	1	SNP	p	A121D	1	.	.	361	363	GAC	785	787	GAC	257;258;256	G,T;A,C;C,T,G	256,1;256,2;254,1,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2968	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1605	222.4	1	SNP	p	D121N	0	.	.	361	363	GAC	785	787	GAC	257;258;256	G,T;A,C;C,T,G	256,1;256,2;254,1,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9902	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5209	236.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2132	2134	AAT	270;269;267	A;A;T,C	270;269;266,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1468	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1503	122.0	1	SNP	p	V57M	1	.	.	169	171	ATG	738	740	ATG	251;251;251	A;T;G,T	251;251;250,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
